Republic Services Inc. Common Stock vs Summit Therapeutics Inc — how do they compare? Republic Services Inc. Common Stock trades at $227 (market cap $68.73B), while Summit Therapeutics Inc trades at $15 (market cap $12.38B). The key difference: Republic Services Inc. Common Stock is far larger — about 5.6× Summit Therapeutics Inc's market cap, and Republic Services Inc. Common Stock pays a 1.19% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RSG | SMMT | |
|---|---|---|
Market Cap | $68.73B | $12.38B |
Volume | 1,226,777 | 7,111,626 |
Sector | Industrials | Health |
52-Week High | $232.27 | $26.38 |
52-Week Low | $197.73 | $12.43 |
Enterprise Value | $82.91B | $11.71B |
Dividend Yield | 1.19% | — |
Typical Hold Time | — | 16 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today but remains volatile following recent positive developments. The stock shows a bullish technical signal with strong moving average support and neutral oscillators. Fundamentally, the company reports no revenue and significant losses (-$1.08B net income for 2025), but recent news includes a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, driving investor optimism.
The outlook is cautiously optimistic due to strong analyst support (65% buy ratings) and a $29.33 consensus price target, representing significant upside. Key risks include ongoing cash burn, lack of current revenue, and clinical trial execution. The AstraZeneca partnership provides substantial validation and funding, but investors should monitor upcoming Q3 2026 earnings and clinical milestones for sustained momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Republic Services Inc. is a waste management company that provides non-hazardous solid waste collection, transfer, disposal, and recycling services across North America.
Read more on RSG →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →